Navigation Links
Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Date:8/14/2014

Pain AmiKet has Orphan Drug Designation for Post Herpetic Neuralgia (PHN).

Operating Results for the Quarter Ended June 30, 2014

  • As of June 30, 2014, we had approximately $3.2 million in cash. In addition, we have $5 million available to us in a revolving line of credit obtained from a related party in April 2014. In addition, in August 2014, we secured a $1 million additional investment. We believe these resources to be sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements over the next twelve months.

  • Our loss from operations was approximately $3.0 million for the quarter ended June 30, 2014 (including $1.2 million of non-cash costs).

  • Our non-operating income was approximately $3.3 million for the quarter ended June 30, 2014, mainly due a decrease in the value of our derivative warrants issued in March 2014.

  • In June 2014, we amended certain terms of our Preferred C Convertible Stock. As a result of the amendment, all then outstanding Preferred C Stock, in the total value of $1.9 million, were reclassified from mezzanine equity into the stockholders equity of the Company. In consideration for their consent, a two-year warrant, valued at $0.4 million, was issued to the holders, such warrants were accounted for within our equity.

    On a per share basis, our total net loss was $0.03 per basic share for the quarter ended June 30, 2014, compared to a net loss of $0.65 per basic share for the quarter ended June 30, 2013.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development   for moderat
'/>"/>

SOURCE Immune Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novimmune Reports Successful Completion of Phase I trial for NI-0101
2. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
3. UMD Researcher Helps Arm the Immune System to Fight Cancer
4. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
5. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
6. Global Autoimmune Disease Diagnostics Market
7. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
8. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
9. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
10. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... THOUSAND OAKS, Calif. , March 2, 2015 /PRNewswire/ ... that it will present 15 abstracts, including data evaluating ... Corlanor ® (ivabradine), an investigational drug for chronic ... 64 th Annual Scientific Session (ACC.15), being held ... Repatha is a fully human monoclonal antibody ...
(Date:3/2/2015)... , March 2, 2015  BC Technical, the ... has acquired Eclipse Systems, a Nuclear Imaging service ... As part of their ongoing vision to provide ... affordable rate, BC Technical continues to expand their ... Technical to add valuable resources and knowledge in ...
(Date:3/2/2015)... Click here for additional information on the ... DPLO ), the nation,s largest independent specialty pharmacy, announced ... 2014. All comparisons, unless otherwise noted, are to the quarter ... Quarter 2014 Highlights include: , Revenue of $612 ... of 208,000, an increase of 11% , Gross margin ...
Breaking Medicine Technology:Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11BC Technical Acquires Eclipse Systems 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 2Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 3Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 4Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 5Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 6Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 7Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 8Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 9Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 10Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 11Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 12Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 13Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 14Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 15Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 16Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 17Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 18Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 19Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 20Diplomat Announces 4th Quarter and 2014 Year End Financial Results; Provides Initial 2015 Guidance 21
(Date:3/2/2015)... ANTONIO (PRWEB) March 02, 2015 After ... quality processes, customer service, pricing and long-term strategy, Blood ... its vendor of choice for member centers’ testing needs. ... centers and represents more than 30 percent of the ... member meeting. , “BCA is committed to drive cost ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... Recovery at Recovery Unplugged™—will be delivering a plenary ... Singer/Songwriter's Perspective on the Art of Healing and ... Disorders (NCAD) and Behavioral Healthcare Executive Summit (BHES).     ... name, Mr. Supa’s songs have been recorded by ...
(Date:3/2/2015)... Over the last five years the ultrasound ... to expand their geographic presence and achieve economies of ... $6.2 billion by 2019 at CAGR of 5.1% from ... and Canada and a major part of Europe are ... as Asia-Pacific including China and India, Latin America and ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
(Date:3/2/2015)... 2015 LegitScript, LLC, operator ... programs, including those for Internet pharmacy certification, ... and classification, has launched a certification program ... new program, called iCareRx , provides ... the identity of the owner/operator of Internet ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2
... Pa., July 31 As tens of thousands of ... China, the,prospect of unexpected injury or illness -- and ... of many., "Finding adequate, appropriate medical care in ... their trip can give themselves,peace of mind," said Angelo ...
... (Nasdaq:,CYBX) today announced that the company will report financial results ... year ending April 24,2009 on Thursday, August 21, 2008 at ... discuss those results on the same day at 9:00 AM ... Instructions, To listen to the conference call live by ...
... Help plans attract, retain and manage consumers. , ... ... Connextions Inc. as a Marketing Applications vendor in its "Hype Cycle ... helps health insurance plans to attract, retain and manage individual ...
... Kenneth O.,Klepper, president & chief operating officer, Medco Health ... the BMO Capital Markets 2008 Focus on,Healthcare Conference in ... presentation at the Millennium Broadway Hotel will begin at ... also scheduled to,attend., The presentation may be heard ...
... When Kirk Manuel speaks,you hear anguish in his voice. You ... members of his community impacted by HIV and AIDS., When ... hear a,man who believes in his product, Head Strong Condoms, and ... a town in Arkansas, a town that has lost,several residents to ...
... new studies examine the use of the nucleoside polymerase ... The reports appear in the August issue of ... Sons on behalf of the American Association for the ... online at Wiley Interscience ( www.interscience.wiley.com ). , ...
Cached Medicine News:Health News:Americans Attending Beijing Olympics Should Plan Ahead for Medical Emergencies 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 3Health News:Medco to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference 2Health News:African American-Owned Condom Company Fears the Widening AIDS Epidemic 2Health News:New treatment therapy helps inhibit hepatitis C 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: